NASDAQ$ASRT
Assertio Holdings Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported an increase in net product sales and raised the full year outlook.
Assertio Holdings, Inc. reported a strong first quarter with an 18% increase in net product sales, driven by Indocin and Sympazan. The company is raising its full-year net product sales and adjusted EBITDA outlook. They also announced the acquisition of Spectrum Pharmaceuticals.
- Net product sales increased by 18% year-over-year, reaching $41.8 million.
- Adjusted EBITDA increased to $25.6 million, up from $23.9 million in the prior year quarter.
- The company strengthened its balance sheet through a $30.0 million exchange of convertible debt.
- Assertio announced the acquisition of Spectrum Pharmaceuticals, expected to close in the third quarter of 2023.
Headline financials
Revenue & EPS history
Assertio · Revenue · Quarterly
$42.5M
Revenue by segment
Assertio · $40.1M total across 1 segment · Q2 2023
- Net Product Sales$40.1M—100.0%
Forward guidance
Assertio is raising its full-year 2023 financial guidance, reflecting confidence in the company's performance and growth prospects. The guidance does not include the effect of the Spectrum acquisition.
Tailwinds
- Net Product Sales (GAAP) raised to $157.0 Million to $167.0 Million
- Adjusted EBITDA (Non-GAAP) raised to $90.0 Million to $98.0 Million
- The company anticipates clinical trial costs in the second half of the year.
- Assertio intends to update its guidance to include the effect of the acquisition after closing, currently anticipated to take place in the third quarter 2023.
- Company expects significant and sustainable growth over the coming years
Headwinds
- Guidance does not include the effect of the Spectrum acquisition.
- Full year Adjusted EBITDA guidance includes an initial estimate of the anticipated clinical trial costs in the second half of the year.
- GAAP net loss of $3.5 million
- Increased operating expenses, including $2.4 million in transaction costs associated with the pending acquisition of Spectrum Pharmaceuticals, Inc.
- Indocin products which are not patent protected and may face generic competition at any time
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-1.9%
Avg return
Earnings day
-4.4%
Avg return
5 days after
-4.7%
Avg return
30 days after
52%
33 / 64 earnings
Positive
+33.3%
Q3 2021
Best reaction
-46.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | +4.2% | — | |
| Q4 2025 | +6.5% | +13.6% | +53.1% | |
| Q3 2025 | +13.3% | -1.2% | -1.2% | |
| Q1 2025 | -1.8% | +8.1% | +0.0% | |
| Q4 2024 | -7.5% | -7.7% | -20.5% | |
| Q3 2024 | +0.2% | -4.7% | +12.9% | |
| Q2 2024 | -12.8% | -14.4% | +0.8% | |
| Q1 2024 | +7.8% | -6.8% | -2.9% | |
| Q4 2023 | +10.8% | +23.1% | -1.1% | |
| Q3 2023 | -45.5% | -53.2% | -50.9% | |
| Q2 2023 | -46.2% | -41.0% | -39.0% | |
| Q1 2023 | +20.6% | +22.2% | -3.8% | |
| Q4 2022 | +7.9% | -15.1% | -0.6% | |
| Q3 2022 | -0.4% | +10.4% | +38.1% | |
| Q2 2022 | -4.3% | -4.8% | -32.6% | |
| Q1 2022 | +6.2% | +37.5% | +52.9% | |
| Q4 2021 | +13.8% | -0.5% | +56.9% | |
| Q3 2021 | +33.3% | +36.0% | +18.4% | |
| Q2 2021 | -2.3% | -3.1% | -16.3% | |
| Q1 2021 | +11.8% | -3.9% | -11.8% | |
| Q4 2020 | +4.3% | -3.2% | -35.1% | |
| Q3 2020 | -41.8% | -40.3% | -37.3% | |
| Q2 2020 | -13.8% | -18.1% | -23.4% | |
| Q1 2020 | +1.3% | +1.2% | +21.3% | |
| Q4 2019 | -35.1% | -29.8% | -37.7% | |
| Q3 2019 | -9.6% | -13.3% | -14.5% | |
| Q2 2019 | +1.4% | -45.1% | -54.2% | |
| Q1 2019 | -0.4% | -10.8% | -37.9% | |
| Q4 2018 | -5.8% | -12.7% | +26.8% | |
| Q3 2018 | +6.5% | +5.5% | -16.3% | |
| Q2 2018 | -19.0% | -23.0% | -33.5% | |
| Q1 2018 | +26.5% | +23.5% | +10.6% | |
| Q4 2017 | -11.4% | -12.3% | -15.0% | |
| Q3 2017 | +15.4% | +30.0% | +68.6% | |
| Q2 2017 | -35.1% | -33.3% | -37.4% | |
| Q1 2017 | +2.3% | +9.0% | -3.1% | |
| Q4 2016 | +4.7% | -0.9% | -9.9% | |
| Q3 2016 | -16.1% | -8.0% | -12.1% | |
| Q2 2016 | +5.6% | +10.2% | +8.7% | |
| Q1 2016 | -6.2% | — | — | |
| Q4 2015 | -4.1% | — | — | |
| Q3 2015 | +6.7% | — | — | |
| Q2 2015 | -7.2% | — | — | |
| Q1 2015 | -14.1% | — | — | |
| Q4 2014 | +13.4% | — | — | |
| Q3 2014 | -2.7% | — | — | |
| Q2 2014 | +5.5% | — | — | |
| Q1 2014 | -23.5% | — | — | |
| Q4 2013 | +14.8% | — | — | |
| Q3 2013 | -0.5% | — | — | |
| Q2 2013 | +4.0% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q4 2012 | +6.2% | — | — | |
| Q3 2012 | +1.5% | — | — | |
| Q2 2012 | -0.5% | — | — | |
| Q1 2012 | +3.2% | — | — | |
| Q4 2011 | +3.3% | — | — | |
| Q3 2011 | -10.4% | — | — | |
| Q2 2011 | +3.1% | — | — | |
| Q1 2011 | -1.2% | — | — | |
| Q4 2010 | +0.6% | — | — | |
| Q3 2010 | -0.2% | — | — | |
| Q2 2010 | +5.2% | — | — | |
| Q1 2010 | -4.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro